Financial Lp Hrt Buys 6,755 Shares of Shuttle Pharmaceuticals (NASDAQ:SHPH) Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt bought 6,755 shares of the firm’s stock in a transaction on Tuesday, June 30th. The shares were purchased at an average cost of $3.23 per share, with a total value of $21,818.65. Following the transaction, the insider directly owned 78,597 shares in the company, valued at approximately $253,868.31. This trade represents a 9.40% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Wednesday, July 1st, Financial Lp Hrt purchased 3,959 shares of Shuttle Pharmaceuticals stock. The shares were purchased at an average price of $3.30 per share, with a total value of $13,064.70.
• On Monday, June 29th, Financial Lp Hrt purchased 25,836 shares of Shuttle Pharmaceuticals stock. The stock was purchased at an average price of $3.44 per share, for a total transaction of $88,875.84.

Shuttle Pharmaceuticals Stock Performance

NASDAQ:SHPH opened at $3.65 on Friday. The firm’s fifty day moving average is $5.80 and its 200-day moving average is $10.64. Shuttle Pharmaceuticals Holdings, Inc. has a 52 week low of $2.90 and a 52 week high of $55.90. The firm has a market cap of $2.34 million, a P/E ratio of -0.08 and a beta of 0.29.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.60 earnings per share for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of SHPH. Geode Capital Management LLC acquired a new stake in Shuttle Pharmaceuticals in the fourth quarter worth $26,000. Boothbay Fund Management LLC acquired a new position in Shuttle Pharmaceuticals during the 4th quarter valued at about $37,000. Ikarian Capital LLC bought a new stake in Shuttle Pharmaceuticals during the 4th quarter worth approximately $124,000. Finally, Connective Capital Management LLC bought a new stake in Shuttle Pharmaceuticals during the 3rd quarter worth approximately $357,000. Institutional investors and hedge funds own 4.58% of the company’s stock.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .